Market Size of miRNA Sequencing and Assay Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 10.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
MiRNA Sequencing And Assay Market Analysis
The miRNA sequencing and assay market is expected to register a CAGR of 10.9% during the forecast period.
- The COVID-19 pandemic significantly impacted healthcare systems worldwide, leading to disruptions in usual care and exposing vulnerable cancer patients to increased risks. While vaccines have been approved to combat SARS-CoV-2 infection, miRNAs have emerged as a potential alternative. These miRNAs can detect SARS-CoV-2 infection by binding to its genome and limiting its post-transcriptional expression, thereby reducing the severity of COVID-19 disease.
- Notably, miR-21-3p has demonstrated the strongest binding affinity to the human coronavirus genome. With the rising number of COVID-19 cases, there is increasing demand for effective treatments, including next-generation sequencing technologies and miRNA sequencing.
- In addition to their potential in COVID-19 pathogenesis, miRNAs are critical in assessing the development, progression, prognosis, diagnosis, and treatment response in cancer patients. Some miRNAs function as tumor suppressors, while others act as oncogenes. For example, miR-451 has been identified as a potential prognostic factor in head and neck squamous cell carcinomas (HNSCCs) through miRNA profiling. The clusters of miR-375 and miR-106b-25 are implicated in the development and progression of HNSCCs. Furthermore, miRNAs have shown promise in forensic medicine due to their stability and specificity, making them useful for degraded samples or complex mixes.
- Investments in genomics have increased in recent years, with companies such as Ultima Genomics and Deep Genomics receiving significant funding for their sequencing and AI discovery platforms. Despite this growth, the market for miRNA sequencing may be hindered by a lack of expertise and computing infrastructure.
- Overall, the market for miRNA sequencing is expected to witness strong growth due to the increasing demand for effective COVID-19 treatments and the critical role of miRNAs in cancer diagnosis and treatment. However, addressing the challenges related to expertise and computing infrastructure will be crucial for sustaining this growth.
